Background. Q fever is an infection caused by Coxiella burnetii. Persistent infection (chronic Q fever) develops in 1%-5% of patients. We hypothesize that inefficient recognition of C. burnetii and/or activation of host-defense in individuals carrying genetic variants in pattern recognition receptors or adaptors would result in an increased likelihood to develop chronic Q fever.
Q fever is an infection with the intracellular gramnegative bacterium Coxiella burnetii. Although most symptomatic individuals experience only mild flulike symptoms or pneumonia (acute Q fever), some patients develop a persistent infection with severe complications including endocarditis and vascular ( prosthesis) infection (chronic Q fever). Persistent infection occurs in 1%-5% of C. burnetii-infected subjects and develops insidiously, which contributes to its late diagnosis and high mortality rates. It is well established that the main risk factors for chronic infection are preexisting abnormalities of cardiac valves (including valvular prosthesis), vascular aneurysms, vascular prosthesis, and immunosuppression [1, 2] . However, in a large outbreak in the Netherlands from 2007 to 2010, only a minority of patients with these risk factors developed chronic Q fever after (serological evidence of ) infection with C. burnetii [3, 4] . Inefficient early recognition of the bacterium by the innate immune system followed by incomplete eradication and/or inadequate initiation of adaptive immune responses may be a contributing factor in the development of chronic Q fever.
The innate immune system provides the first barrier against C. burnetii infection. In general, pattern recognition receptors (PRRs) on innate immune cells recognize molecular moieties of microorganisms. Toll-like receptors (TLRs) and nucleotide-binding oligomerization domain (NOD) proteins are the main PRRs involved in the recognition of bacteria. TLRs interact with various adaptor proteins, including myeloid differentiation primary response protein 88 (MyD88) and Toll interleukin 1 receptor domaincontaining adaptor protein (TIRAP), to activate transcription factors, leading to production of proinflammatory cytokines, activation of antimicrobial mechanisms, and subsequent initiation of adaptive immune responses. MyD88 is also required for the production of interleukin 1, 18, and 33, which emphasizes its importance for host defense against microorganisms.
We recently demonstrated that C. burnetii-induced cytokine production by human innate immune cells is mediated through the heterodimer TLR1/TLR2 on the cell membrane and by cytoplasmic NOD2 [5] . TLR6 seems to be involved specifically in the recognition of the C. burnetii strain 3262 that was isolated during the outbreak in the Netherlands [5] . Microorganisms such as C. burnetii use phagocytosis as an efficient mechanism of entry into monocytes/macrophages, where they can survive intracellularly in a parasitophorous vacuole (PV) [6] . An important role in C. burnetii uptake has been described for leukocyte response integrin (α v β 3 integrin) and complement receptor 3 (CR3 [αMβ 2 , CD11b/CD18]). Virulent phase I C. burnetii uptake is mediated by α v β 3 integrin, whereas phagocytosis of avirulent phase II C. burnetii also involves CR3 [7, 8] .
Genetic variants in immune cell receptors such as TLRs and NODs and their adaptors have been associated with increased susceptibility to bacterial infections [9] [10] [11] [12] [13] [14] [15] [16] . Thus, it is tempting to speculate that inefficient recognition of C. burnetii and activation of host defense in individuals carrying genetic variants in these receptors or adaptors would result in ineffective early clearance of the bacterium and an increased likelihood to develop chronic Q fever. No study so far has been able to investigate this possibility, due to the low prevalence of the disease. The recent Q fever outbreak in the Netherlands led to >4000 reported acute Q fever cases and >250 chronic Q fever cases [17] , offering an unique opportunity to study this question.
We hypothesized that certain polymorphisms in the host's PRR genes or in genes encoding their adaptor proteins influence the risk of persistent C. burnetii infection and hence the development of chronic Q fever. To test this hypothesis, we analyzed the prevalence of specific single-nucleotide polymorphisms (SNPs)   in 11 candidate genes-TLR1, TLR2, TLR4, TLR6, TLR8,  MYD88, TIRAP, NOD2, ITGAV, ITGB3 , and ITGAM (CD11b)-in a cohort of 139 patients with chronic Q fever and a control cohort of 220 individuals, living in the same area and with valvular or vascular predisposing factors for chronic Q fever, who had contracted C. burnetii (based on positive serological results) but did not develop chronic Q fever. The genetic study was complemented with functional assays investigating the effect of the specific polymorphisms on the in vitro cytokine production in C. burnetii-stimulated whole blood.
MATERIAL AND METHODS

Ethics Statement
The study was approved by the Ethical Committee of Radboud University Medical Center, Nijmegen, the Netherlands. Subjects were enrolled after providing written informed consent (or waiver when deceased [n = 5], as approved by the Ethical Committee). Institutional review boards of participating hospitals approved the inclusion of patients and controls in this study. The study has been performed in accordance with the Declaration of Helsinki.
Subjects
All patients who visited the outpatient clinic at the internal medicine departments of the participating hospitals with probable or proven chronic Q fever, as defined by the Dutch consensus on chronic Q fever (Table 1) , were asked to participate in the study. Recruitment of patients took place between July 2011 and July 2014 at Radboud University Medical Center, CanisiusWilhelmina Hospital (Nijmegen), Catharina Hospital (Eindhoven), Elkerliek Hospital (Helmond), Atrium Medical Center (Heerlen), Elisabeth Hospital (Tilburg), Bernhoven Hospital (Oss), and Jeroen Bosch Hospital ('s-Hertogenbosch). Demographic and clinical characteristics (classification based on serological titers and imaging results, cardiovascular risk factors, immunosuppressive comorbid condition, or medication) were retrieved from the patients' medical records.
The population-matched control group consisted of individuals from the same area who had valvular or vascular abnormalities predisposing to chronic Q fever and serological evidence of exposure to C. burnetii (anti-C. burnetii phase II immunoglobulin G antibody titer ≥1:32) but no clinical symptoms or serological evidence of chronic Q fever. These individuals were recruited in the Q fever prevaccination screening campaign in JanuaryApril 2011 [20, 21] and in a Q fever screening of patients with vascular risk factors living in the Q fever outbreak area [22] .
Genotyping
From patients who came to the outpatient clinic or to the Q fever prevaccination screening, venous blood was collected and stored at −80°C. DNA was isolated from these blood samples using standard methods [23] . Other participants, both patients and controls, received a buccal swab kit (Isohelix) to obtain epithelial cells for DNA isolation. DNA was isolated using a buccal DNA isolation kit (Isohelix), according to the manufacturer's protocol. SNPs were selected based on known effects on protein function or gene expression, published associations with human diseases, and/or haploview data. In total, 25 SNPs in TLR1, TLR2, TLR4, TLR6, TLR8, TIRAP, MYD88, NOD2, ITGAV, ITGB3, and ITGAM were genotyped with a Sequenom mass spectrometry genotyping platform. Quality control was performed by duplicating 5% of the samples within and across plates, incorporating positive and negative control samples, and sequencing samples to verify the various genotypes.
In Vitro Whole-Blood Stimulation and Cytokine Measurements
In a subgroup of control subjects-those who participated in the Q fever prevaccination screening study, as described elsewhere [24] -whole-blood assays were performed, and C. burnetii-induced cytokines were measured (n = 93). In short, venous blood was drawn into endotoxin-free lithium-heparin tubes (Vacutainer; BD Biosciences), and samples were processed within 12 hours. Blood was aliquoted in separate tubes and incubated at 37°C for 24 hours with heat-inactivated (30 minutes at 99°C) C. burnetii Nine Mile RSA493 phase I [25] (bacteria count, 10 7 /mL) or mitogen ( positive control) or without stimulus (negative control), as described elsewhere [24] . After incubation, blood cultures were centrifuged at 4656 g for 10 minutes, and supernatants were collected. Supernatants were stored at −20°C until concentrations of cytokines-including interleukin 1β (IL-1β), tumor necrosis factor (TNF), interleukin 2 (IL-2), interleukin 6 (IL-6), and interleukin 10 (IL-10)-were measured with a magnetic bead multiplex assay (Merck Millipore), according to the manufacturer's instructions.
Statistical Analyses
The presence of Hardy-Weinberg equilibrium was analyzed for all 24 SNPs separately in the control cohort [26] . For the 2 TLR8 SNPs on the X chromosome, only the female subjects were included in the Hardy-Weinberg equilibrium analysis, and relative allele frequencies were subsequently compared between female and male subjects. The difference in genotype frequencies between patients and controls were analyzed by means of a gene dosage model, using the Fisher exact test to test for significance. Subsequent dominant and recessive model analysis was performed using univariate logistic regression, for which odds ratios (ORs) and their 95% confidence intervals (CIs) were reported. Because the choice of the genetic variants was based exclusively on genes with an established or suspected role in C. burnetii recognition, rather than exploratory, no correction for multiple testing was performed. Statistical analyses were performed with SPSS software (version 20). Cytokine concentrations from the whole-blood stimulation assays were stratified according to genotype and compared by means of Mann-Whitney U tests, using GraphPad Prism software (version 5; GraphPad). Overall, statistical tests were 2 sided, and differences were considered statistically significant at P < .05. Abbreviations: AUS, abdominal ultrasound; CRP, C-reactive protein; CT, computed tomography; ESR, erythrocyte sedimentation rate; FDG-PET, fluorodeoxyglucose positron emission tomography; IFA, immunofluorescence assay; IgG, immunoglobulin G; MR, magnetic resonance; PCR, polymerase chain reaction; TEE, transesophageal echocardiography; TTE, transthoracic echocardiography. a The consensus guidelines are described by Wegdam-Blans et al [19] . b In the absence of acute infection.
c Cutoff is dependent on the IFA technique used (≥1:800 for a technique developed in house and ≥1:1024 for a commercial IFA technique).
RESULTS
Baseline Characteristics
In total, 139 (92 proved and 47 probable) patients with chronic Q fever and 220 control subjects without chronic Q fever but with serological evidence of C. burnetii exposure and a risk factor for chronic Q fever were included in the study. Demographic and clinical characteristics of patients and controls are summarized in Table 2 . Patients were slightly older than controls (2.4-year difference in median age). In both groups, vascular risk factors were more prevalent than cardiac valvular risk factors. Valvular risk factors, however, were more prevalent in the controls than in the patients. Patients with chronic Q fever were more likely than control subjects to be immunocompromised.
Association of SNPs in MYD88, NOD2, and TLR1 With Chronic Q Fever
Genotyping of patients and controls was successful for all polymorphisms in genes encoding TLRs, NOD2, MyD88, TIRAP, α v β 3 integrin, and CR3 presented in Table 3 . For each polymorphism, >94% of the subjects were genotyped. All SNPs were in Hardy-Weinberg equilibrium in the control group, except for ITGB3 rs4642 (χ 2 = 6.18); this SNP was excluded from further analysis.
In the analysis of all patients with chronic Q fever, a significantly different distribution of 1 NOD2 and 1 MYD88 polymorphism was revealed in the dominant model: NOD2 L1007fsX1 (P = .02; OR, 3.34; 95% CI, 1.22-9.14) and MYD88 −938C>A (P = .04; OR, 2.15; 95% CI, 1.05-4.39) ( Table 4) . Compared with controls, patients were more often heterozygous for the allelic variant of these SNPs.
When only patients with proven chronic Q fever were considered, TLR1 R80T was distributed significantly different among patients and controls in the dominant model (P = .03; OR, 0.48; 95% CI, .24-.95) ( Table 5) , whereas it was marginally significant (P = .08; OR, 0.61; 95% CI, .35-1.06) when all patients (including those with probable Q fever) were included. Patients were less often heterozygous or homozygous for the allelic variant of this SNP. The distributions of NOD2 L1007fsX1 and MYD88 −938C>A showed a trend toward significance among patients and controls (P = .07 and P = .09, respectively) when only patients with proven chronic Q fever were included in the analysis. No associations were observed between polymorphisms in TLR2, TLR4, TLR6, TIRAP, ITGAV, ITGB3, or ITGAM and the development of chronic Q fever.
Effect of TLR1 SNP R80T on In Vitro IL-10 Production by C. burnetii-Stimulated Whole Blood
The functional consequences of TLR1 R80T, NOD2 L1007fsX1 and MYD88 −938C>A were studied using C. burnetii stimulation of whole blood obtained from 93 control subjects with different TLR1 R80T, NOD2 L1007fsX1, and MYD88 −938C>A genotypes. Production of IL-1β, TNF, IL-2, IL-6, and IL-10 was measured after 24 hours of stimulation. Decreased IL-10 production was observed after stimulation with C. burnetii by blood cells with TLR1 80T containing genotypes, which is associated with lower susceptibility to chronic Q fever. Proinflammatory cytokine production, including IL-1β, IL-6, TNF, and IL-2, did not differ among TLR1 R80T genotypes (Figure 1 ).
There were no significant differences in the association between NOD2 L1007fsX1 and MYD88 −938C>A polymorphisms and the production of IL-1β, TNF, and IL-10 in response to C. burnetii (Figure 2 ). Findings for IL-6 and IL-2 are not shown (P = .78 and P = .58 respectively, with stratification by NOD2 1007fsX1 genotype; P = .51 and P = .52 with stratification by MYD88 −938C>A genotype). c In case patients, immunocompromised states included autoimmune disease with immunosuppressive drug treatment (n = 14), renal insufficiency (n = 1), renal transplantation (n = 1), cancer (n = 3), and prednis(ol)one use (n = 1); in controls, autoimmune disease with immunosuppressive drug treatment (n = 5), renal transplantation (n = 2), cancer (n = 4); and prednis(ol)on use (n = 4).
DISCUSSION
In the present study, we investigated whether genetic variants in PRRs and adaptor proteins were associated with chronic Q fever in C. burnetii-infected individuals with vascular or valvular risk factors. Our results showed that TLR1 R80T (rs5743611), NOD2 L1007fsX1 (rs2066847) and MYD88 −938C>A (rs4988453) are linked to the development of chronic Q fever. In addition, blood cells from individuals carrying the TLR1 80T variant that led to decreased susceptibility to chronic Q fever showed lower IL-10 production with C. burnetii stimulation. We observed no influence of TLR2, TLR4, TLR6, TLR8, TIRAP, ITGAV, ITGB3, and ITGAM SNPs on the susceptibility to chronic Q fever. To our knowledge, this is the first genetic study investigating the role of SNPs in PRR and adaptor molecule genes in the development of chronic Q fever, the most severe complication of C. burnetii infection. Our study comprises the largest chronic Q fever cohort ever described. Previous studies on genetic predisposition to Q fever either concerned small cohorts of patients or focused on other clinical Q fever manifestations (acute Q fever or Q fever fatigue syndrome). Everett et al [27] studied susceptibility to acute Q fever by focusing on TLR2 and TLR4 SNPs, for which they demonstrated no correlation in 89 patients with acute Q fever and 162 controls. Helbig et al [28] investigated association between variants in HLA, IFNG, IL10, and TNFR genes and chronic Q fever or post-Q fever fatigue in 22 and 31 patients, respectively; they described significant differences in the frequencies of IL10 promoter microsatellites in chronic Q fever compared with findings in 181 individuals without Q fever exposure. Vollmer-Conna et al [29] demonstrated that functional polymorphisms in IFNG and IL10 affect disease severity and duration after serologically confirmed acute Q fever.
We focused on polymorphisms in immune genes involved in the initial recognition of C. burnetii, based on the assumption that chronic Q fever develops only after inefficient early recognition resulting in inadequate early clearance of the bacterium. Previous studies have shown that patients with chronic Q fever exhibit a different cytokine response to C. burnetii [30] [31] [32] , but it is not clear whether this different response is specific for the myeloid cells of these individuals or due to the persistent presence of the bacteria in monocytes/macrophages. Deciphering genetic polymorphisms in immune genes of the innate response to C. burnetii may give more insight into the mechanism.
In genetic association studies, the choice of the control group is of pivotal importance. We deliberately chose a control cohort of subjects living in the same Q fever-endemic area, with both past C. burnetii infection (as shown by positive anti-C. burnetii serological results) and cardiovascular risk factors for chronic Q fever, who did not develop chronic Q fever. When a different distribution of genetic polymorphisms is observed between patients and these controls, it indicates that these polymorphisms modify the risk of developing chronic Q fever, and not that of contracting C. burnetii infection or any underlying predisposing factors. The control cohort, however, was somewhat younger, had significantly more valvular risk factors, and was less immunocompromised than the patient cohort.
Notably, antimicrobial drug treatment at the time of acute Q fever might decrease the risk of chronic Q fever. Although information on previous treatment for acute Q fever was not obtained from the controls in this study, we assume that the majority of controls did not receive antibiotic treatment for acute Q fever because they participated in screening programs to detect previous C. burnetii infection.
The patient cohort included patients with proven or probable diagnosis of chronic Q fever; possible cases were left out. Given that the diagnosis of chronic Q fever is difficult-because direct detection of the bacterium is not possible in many cases-a probable chronic Q fever diagnosis is based on indirect evidence of persistent C. burnetii infection. These patients also receive long-term antibiotic treatment, with treatment and follow-up protocols identical to those used for proven chronic Q fever, but some of these patients may have no persistent infection. However, we also performed an analysis including only the subset of patients with proven chronic Q fever, which increased the level of diagnostic certainty for chronic Q fever in the case patients but decreased the power to detect associations. We identified a significant association between the TLR1 R80T polymorphism and the risk of chronic Q fever. This TLR1 SNP has been described as a risk factor for invasive aspergillosis after hematopoietic stem cell transplantation [16] , candidemia [33] , and inflammatory bowel disease [34] . TLR1 S248N, which is not linked to TLR1 R80T, did not show an association with the development of chronic Q fever. We studied the functional consequences of the TLR1 R80T polymorphism in a subset of controls. The presence of TLR1 80T allele resulted in significantly lower production of the anti-inflammatory cytokine IL-10 but did not affect TNF, IL-1β, or other proinflammatory cytokines, as reported elsewhere [5] . The TLR1 80T allele was significantly less frequent in the patients with proven Q fever than in the control cohort. This suggests that having Figure 1 . Association between TLR1 R80T genotypes and cytokine production after whole-blood stimulation with Coxiella burnetii. IL-1β, interleukin 1β; IL-2, interleukin 2; IL-6, interleukin 6; IL-10, interleukin 10; TNF, tumor necrosis factor. Stimulation was performed for 24 hours with heat-killed C. burnetii Nine Mile phase I (RSA 493) (bacteria count, 1 × 10 lower IL-10 production on contact with C. burnetii may protect against chronic Q fever. This finding is in line with the role of the anti-inflammatory cytokine IL-10 in the development of human chronic Q fever, which has been extensively reported [30, [35] [36] [37] . In short, IL-10 induces C. burnetii replication in naive monocytes [35] . In addition, IL-10 production in unstimulated peripheral blood mononuclear cells was increased after C. burnetii infection in individuals who subsequently developed chronic endocarditis relative to those who did not [36] . Moreover, transgenic mice that constitutively overexpress IL-10 is the only efficient model for chronic Q fever so far [38] . Figure 2 . Association between NOD2 and MYD88 genotypes and cytokine production after whole-blood stimulation with Coxiella burnetii. Subjects were stratified by genotype for NOD2 1007fsX1 (A, C, and E ) and MYD88 −938C>A (B, D, and F). Stimulation was performed for 24 hours with heat-killed C. burnetii Nine Mile phase I (RSA 493) (bacteria count, 1 × 10 7 /mL). Data are presented as medians and interquartile ranges, and groups were compared with the Mann-Whitney U test. Abbreviation: IL-1β, interleukin 1β; IL-10, interleukin 10; TNF, tumor necrosis factor.
NOD2 is a cytoplasmic receptor involved in bacterial peptidoglycan sensing. The intracellular localization of NOD2 and the survival of C. burnetii in the intracellular PV may lead to ongoing interaction between them. The active secretion of bacterial proteins by C. burnetii through the PV membrane, demonstrated to occur by a type IV secretion apparatus [39] , may play a role in this process. Genetic variation in NOD2 has previously been linked to autoinflammatory diseases, such as Crohn disease and Blau syndrome [40] . An association with susceptibility to tuberculosis and leprosy has also been described [41, 42] . The NOD2 L1007fsX1 SNP, leading to a frame shift and a premature stop codon, has a large effect on the protein. Its association with Crohn disease has been extensively described [43, 44] . Ammerdorffer et al [5] showed that C. burnetiiinduced cytokine production by human mononuclear cells is mediated through NOD2, with NOD2-deficient individuals having strongly decreased IL-1β and IL-6 responses. In the present study, we were unable to show a significant effect on C. burnetii-induced cytokine responses when we stratified for the polymorphism NOD2 L1007fsX1, most likely because of the rare occurrence of heterozygotes for the allelic variant and absence of homozygotes.
To our knowledge, the role of the adaptor molecule MyD88 in C. burnetii infection has not been studied previously. We found that MYD88 −938C>A was significantly associated with susceptibility to chronic Q fever. In general, MyD88 plays a central role in innate immune responses, being downstream of all TLRs (except TLR3) and the interleukin 1 receptor. MyD88 deficiency leads to recurrent infections with pyogenic bacteria in early childhood but seems redundant for most other infections [15] . The MYD88 −938C>A SNP has been shown to decrease promoter activity [45] and was found to be associated with development of sarcoidosis [46] . TLR2 is a receptor for bacterial lipopeptides, which are recognized by either TLR2/TLR1 or TLR2/TLR6 heterodimers. Although multiple studies have shown that TLR2 is involved in the host's immune response against C. burnetii [5, 47-49], we found no association between the TLR2 SNPs included in this study and development of chronic Q fever. This could indicate either that TLR2 has no prominent role in the elimination of C. burnetii or that the consequences of these genetic variants for the protein function in C. burnetii defense are limited. We also did not observe any association of chronic Q fever with TLR4, TLR6, TLR8, or TIRAP polymorphisms. Genetic polymorphisms in the genes for the receptors α v β 3 integrin and CR3, which have been reported to be involved in C. burnetii uptake and TNF production [7, 50] , were also not distributed significantly differently between patients with chronic Q fever and controls.
Our study has some limitations that need to be taken into account. Although this is the largest cohort of patients with chronic Q fever ever described, it is still relatively small for a study of the genetic associations of an infectious disease. We tried to overcome this limitation by using a control group almost similar in sex, age, and cardiovascular risk factors and with exposure to the same virulent C. burnetii strain. Another important consideration is that no correction for multiple testing was performed, because only candidate genes with a known or suspected role in C. burnetii recognition were investigated, and not randomly selected genes. It has to be taken into account that when correction for multiple testing is applied, the statistical significance of the NOD2, MYD88, and TLR1 SNPs association with susceptibility to chronic Q fever is lost. To confirm our current findings, they need to be replicated in another cohort of patients with chronic Q fever.
In conclusion, our current findings suggest an association between TLR1, NOD2, and MYD88 polymorphisms and the risk or developing chronic Q fever after infection with C. burnetii. Interestingly, we found that the protective TLR1 80T allele was associated with decreased C. burnetii-induced IL-10 production. Further research is warranted to elucidate the exact role of these receptors and the adaptor molecule in host defense against C. burnetii in humans, which could be used to strategize approaches to risk assessment, prophylactic treatment, or targeted therapy of chronic Q fever.
Notes
